EV-302研究(NCT04223856)为Ⅲ期试验,与铂类化疗(PBC)相比,enfortumab vedotin+帕博利珠单抗(EV+P)使既往未经治疗的局部晚期或转移性尿路上皮癌(la/mUC)患者中位无进展生存期(mPFS)和总生存期(OS)几乎翻了一番。这里将对患者报...
本期,我们有幸邀请到四川大学华西医院魏强教授、辽宁省肿瘤医院胡滨教授与中国医学科学院肿瘤医院深圳医院田军教授,共同探讨EV-302研究更新对我国尿路上皮癌治疗的深远影响。 医脉通:EV-302数据更新将以Rapid Oral形式报告,请您介绍一下...
311108#Background:EV+P nearly doubled median progression-free survival and overall survival vs PBC in patients (pts) with previously untreated la/mUC in the phase 3 EV-302 trial. PROs are reported here.Methods:In EV-302 (NCT04223856) pts were randomized 1:1 to EV+P or PBC (...
1.Powles T,Valderrama BP,Gupta S,Bedke J,Kikuchi E,Hoffman-Censits J,Iyer G,Vulsteke C,Park SH,Shin SJ,Castellano D,Fornarini G,Li JR,GümüşM,Mar N,Loriot Y,Fléchon A,Duran I,Drakaki A,Narayanan S,Yu X,Gorla S,Homet Moreno B,van der Heijden MS;EV-302 Trial Investigators....
- Approval based on the EV-302 trial where the treatment combination nearly doubled median overall survival and significantly extended progression free survival compared to platinum-containing chemotherapy, the current standard of care for first-line treatment of radically unresectable urothelia...
The report was a bit of a tease, however, as the companies did not put numbers to the claim. Those highly anticipated figures are now in for the EV-302 phase 3 trial, and they lend more credence to the idea that the combo has the potential to be “practice-changing,” in the...
Certain statements made in this press release are forward-looking, such as those, among others, relating to continued FDA approval in the referenced indication; the potential for the EV-302 trial to serve as the...
The accelerated approval means Padcev and Keytruda can be used for these patients for the time being, but will have to show a benefit as first-line therapy in the confirmatory EV-302 study, which is due to read out later this year. If the results of this trial are positive, the combin...
EV-302: A two-arm, open-label, randomized controlled phase 3 trial of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (Trial in Progres...
Tesla FSD trial temporarily paused in China, report says EV 2 days ago Dong Yi Chen 0 BYD Qin L EV with “God’s Eye” C and 545 km range enters market starting at 16,500 USD in China EV 3 days ago Dong Yi Chen 3 GWM’s second-gen Haval Xiaolong Max PHEV pre-sale starts at ...